Kymriah genetically modified autologous T cells for infusion Images
Generic Name: tisagenlecleucel
This medication has been identified as Kymriah genetically modified autologous T cells for infusion. It is supplied by Novartis Pharmaceuticals Corporation.
Kymriah is used in the treatment of Follicular Lymphoma; Acute Lymphoblastic Leukemia; B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma and belongs to the drug class miscellaneous antineoplastics. Kymriah genetically modified autologous T cells for infusion is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Kymriah
- Generic Name
- tisagenlecleucel
- Strength
- genetically modified autologous T cells for infusion
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Novartis Pharmaceuticals Corporation
- National Drug Code (NDC)
- 00078-0846
More about Kymriah (tisagenlecleucel)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.